XOMA (NASDAQ:XOMA) Shares Cross Above 200 Day Moving Average of $19.93

XOMA Co. (NASDAQ:XOMA - Get Free Report) passed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $19.93 and traded as high as $24.62. XOMA shares last traded at $24.38, with a volume of 7,113 shares traded.

Analyst Upgrades and Downgrades

Separately, HC Wainwright restated a "buy" rating and issued a $74.00 target price on shares of XOMA in a research note on Friday, February 16th.

XOMA Stock Down 0.5 %

The company has a debt-to-equity ratio of 1.34, a current ratio of 8.68 and a quick ratio of 8.68. The stock's 50 day simple moving average is $24.19 and its 200-day simple moving average is $19.93.

XOMA (NASDAQ:XOMA - Get Free Report) last released its quarterly earnings data on Friday, March 8th. The biotechnology company reported ($0.49) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.36) by ($0.13). The business had revenue of $1.83 million during the quarter, compared to analyst estimates of $1.01 million. XOMA had a negative net margin of 886.91% and a negative return on equity of 25.17%. As a group, analysts anticipate that XOMA Co. will post -1.73 EPS for the current fiscal year.

Institutional Trading of XOMA

Several large investors have recently made changes to their positions in XOMA. UBS Group AG boosted its position in XOMA by 9,318.8% during the third quarter. UBS Group AG now owns 1,507 shares of the biotechnology company's stock worth $27,000 after purchasing an additional 1,491 shares during the period. Barclays PLC acquired a new stake in shares of XOMA in the second quarter worth $28,000. BNP Paribas Arbitrage SNC bought a new stake in shares of XOMA during the 2nd quarter worth $36,000. BNP Paribas Financial Markets grew its stake in XOMA by 118.3% in the 4th quarter. BNP Paribas Financial Markets now owns 2,277 shares of the biotechnology company's stock valued at $42,000 after buying an additional 1,234 shares during the last quarter. Finally, Bank of America Corp DE grew its stake in XOMA by 40.7% in the 4th quarter. Bank of America Corp DE now owns 2,380 shares of the biotechnology company's stock valued at $44,000 after buying an additional 689 shares during the last quarter. Institutional investors own 95.92% of the company's stock.

XOMA Company Profile

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.